Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04729257 · ClinicalTrials.gov registry record · NA

Norms Expansion and Validation for IntelliSpace Cognition

A NA study of Cognitive Functioning of Healthy Individuals, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.

Completed
Registry status
NA
Development phase
508
Enrollment target
1
Study location

NCT04729257 is a NA study of Cognitive Functioning of Healthy Individuals that has completed, run by Philips Electronics Nederland B.V. acting through Philips CTO organization. The registered enrollment target is 508 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04729257, a NA study of Cognitive Functioning of Healthy Individuals, has completed, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.

COMPLETED
Registry status
NA
Development phase
508 participants
Enrollment target
1
Study location

Study Summary

This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.

Interventions

  • DEVICE Philips IntelliSpace Cognition (ISC).
  • DIAGNOSTIC_TEST Paper-Pencil Tests.

Study Locations (1)

Pennsylvania

  • Research America Inc. - Newtown Square

Trial Details

FieldValue
Enrollment Target 508 participants
Start Date 2021-03-08
Est. Completion 2021-07-02
Phase NA

What the Registry Record Tells You About NCT04729257

The ClinicalTrials.gov registry entry for NCT04729257 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philips Electronics Nederland B.V. acting through Philips CTO organization, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cognitive Functioning of Healthy Individuals appearing as the primary indexed condition, and to 2 interventions - of which Philips IntelliSpace Cognition (ISC). is the first listed.

NCT04729257 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04729257 about?

NCT04729257 is a clinical study titled "Norms Expansion and Validation for IntelliSpace Cognition". This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.

What is the current status of trial NCT04729257?

This trial is currently completed. It is a NA study. The enrollment target is 508 participants. The study started on 2021-03-08. Estimated completion is 2021-07-02.

What conditions does trial NCT04729257 study?

This clinical trial studies the following conditions: Cognitive Functioning of Healthy Individuals.

What interventions are being tested in trial NCT04729257?

The interventions under investigation include: Philips IntelliSpace Cognition (ISC). (DEVICE), Paper-Pencil Tests. (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04729257?

This trial is sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04729257 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.